Plasma cell tumors Flashcards
Cannon et al. Clinical signs, treatment, and outcome in cats with myeloma-related disorders receiving systemic therapy
15 cases
13 received melphalan or cyclophophamide +/- corticosteroids
CHB was used as rescue therapy with PD
RR for melphalan and cyclophophamide?
Discontinuation of melphalan due to toxicity was common
Survival times for melphalan and cyclophophamide?
71% and 83%
Not different - 252 (8 mo) and 394 days (1 yr)
Thamm et al. 2014. GS-9219/VDC-1101-a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma
Effects of VDC-1101 against 3 human MM cell lines and phase 2 trial with 14 dogs with MM
Treated with 6 doses over 10-15 weeks
Effect on cell lines?
Major antitumor response (reduction in serum paraprotein and resolution of hypercalcemia, peripheral cytopenias and bone marrow plasmacytosis) were observed in 9/11 dogs for median 172 days
2 dogs were euthanized due to presumed pulmonary fibrosis
Dose-dependent anti-proliferative effect
Boostrom et al. 2017. Canine cutaneous plamacytosis: 21 cases
Syndrome of multiple cutaneous plasma cell tumors in the absence of multiple myeloma
21 dogs with CP
Commonly affected breeds?
Lesions?
Most commonly used drug melphalan and prednisone - ORR?
Single agent lomustine, ORR?
Median PFI? OS?
Golden (5/21) and labrador retriever (3/21)
14/21 had >10 lesions with some having >100
74%
71.4%
153 days and 542 days
Fernandez et al. 2018. Comparison of two melphalan protocol and evaluation of outcome and prognostic factors in multiple myeloma in dogs
38 dogs: 17 reveived pulse doses and 21 received daily dose
Overall ST?
Negative prognostic indicators?
Hypercalcemia and osteolytic lesions were not prognostic
930 days
Renal disease and NLR ratio
Takanosu et al. 2018. PCR-based clonality analysis of antigen receptor gene rearrangements in canine cutaneous plasmacytoma
Frequency of IGH clonality in plasmacytoma? DLBCL?
Sensitivity of detecting IGH clonality in canine plasmacytomas was lower than DLBCL - may be due to somatic hypermutation of the variable region
0-35%, 8.7-78.3%
